BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25387409)

  • 1. Monitoring of WT1 and its target gene IRF8 expression in acute myeloid leukemia and their significance.
    Zhang Q; Zhang Q; Li Q; Liu B; Wang Y; Lin D; Zhou C; Li W; Tang K; Tian Z; Wang M; Wang J; Mi Y
    Int J Lab Hematol; 2015 Aug; 37(4):e67-71. PubMed ID: 25387409
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
    Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
    Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients.
    Alonso-Dominguez JM; Tenorio M; Velasco D; Abalo L; Lozano S; Villarrubia J; López-Jimenez J; Grande S; Ayala R
    Cancer Genet; 2012 Apr; 205(4):190-1. PubMed ID: 22559982
    [No Abstract]   [Full Text] [Related]  

  • 4. Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?
    De Marchi F; Candoni A; Zannier ME; Haley L; Lau BW; Fanin R
    Am J Hematol; 2017 May; 92(5):E72-E74. PubMed ID: 28211167
    [No Abstract]   [Full Text] [Related]  

  • 5. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
    Nomdedéu JF; Hoyos M; Carricondo M; Bussaglia E; Estivill C; Esteve J; Tormo M; Duarte R; Salamero O; de Llano MP; García A; Bargay J; Heras I; Martí-Tutusaus JM; Llorente A; Ribera JM; Gallardo D; Aventin A; Brunet S; Sierra J;
    Leukemia; 2013 Nov; 27(11):2157-64. PubMed ID: 23584566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells.
    Vidovic K; Svensson E; Nilsson B; Thuresson B; Olofsson T; Lennartsson A; Gullberg U
    Leukemia; 2010 May; 24(5):992-1000. PubMed ID: 20237505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia.
    El Bordiny M; Al-Ghandour A; Abo Elwafa RA; Fayed O
    Clin Transl Oncol; 2019 Jul; 21(7):864-873. PubMed ID: 30506133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors.
    Ujj Z; Buglyó G; Udvardy M; Beyer D; Vargha G; Biró S; Rejtő L
    Pathol Oncol Res; 2016 Jan; 22(1):217-21. PubMed ID: 26531831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.
    Sakamoto Y; Mariya Y; Sasaki S; Teshiromori R; Oshikiri T; Segawa M; Ogura K; Akagi T; Kubo K; Kaimori M; Funato T
    Tohoku J Exp Med; 2009 Oct; 219(2):169-76. PubMed ID: 19776535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
    Marani C; Clavio M; Grasso R; Colombo N; Guolo F; Kunkl A; Ballerini F; Giannoni L; Ghiggi C; Fugazza G; Ravetti JL; Gobbi M; Miglino M
    Leuk Res; 2013 Dec; 37(12):1606-11. PubMed ID: 23891447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.
    Xu B; Song X; Yip NC; Xiao P; Zhang Y; Wang W; Zhou S
    Hematology; 2010 Apr; 15(2):74-80. PubMed ID: 20423567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia.
    de Leeuw DC; Verhagen HJ; Denkers F; Kavelaars FG; Valk PJ; Schuurhuis GJ; Ossenkoppele GJ; Smit L
    Leukemia; 2016 Mar; 30(3):742-6. PubMed ID: 26108690
    [No Abstract]   [Full Text] [Related]  

  • 13. The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients.
    Shibasaki Y; Seki Y; Tanaka T; Miyakoshi S; Fuse K; Kozakai T; Kobayashi H; Ushiki T; Abe T; Yano T; Moriyama M; Kuroha T; Isahai N; Takizawa J; Narita M; Koyama S; Furukawa T; Sone H; Masuko M
    Leuk Res; 2015 Jun; 39(6):667-71. PubMed ID: 25890432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
    Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of WT1 Gene in Bone Marrow of Patients with Acute Myeloid Leukemia and Its Influence on Prognosis].
    Zheng YT; Li BX; Sun YJ; Yu CL; Sun QY; Qiao JH; Hu KX; Zuo HL; Dong Z; Ai HS; Guo M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):649-54. PubMed ID: 27342485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia.
    Andersson C; Li X; Lorenz F; Golovleva I; Wahlin A; Li A
    Diagn Mol Pathol; 2012 Dec; 21(4):225-33. PubMed ID: 23111196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of WT1 Expression as a Marker of Treatment Outcome in Karyotype Normal Acute Myeloid Leukemia Patients in Pakistan.
    Ahmed ZA; Shaikh MS; Moatter T
    J Coll Physicians Surg Pak; 2016 May; 26(5):441-2. PubMed ID: 27225156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detectable Wilms' tumor-1 transcription at treatment completion is associated with poor prognosis of acute myeloid leukemia: a single institution's experience.
    Yamauchi T; Negoro E; Lee S; Takai M; Matsuda Y; Takagi K; Kishi S; Tai K; Hosono N; Tasaki T; Ikegaya S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Anticancer Res; 2013 Aug; 33(8):3335-40. PubMed ID: 23898100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
    Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
    Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.